ReNeuron moving to purpose-built labs in Wales
23rd Feb 2016 16:05
(ShareCast News) - ReNeuron's office, laboratory and manufacturing staff were preparing for a space upgrade this week, with the firm announcing it was moving from Guildford to Pencoed in South Wales. The AIM-traded stem cell therapy development company said the new location was purpose-built, and wo
Read moreBabcock non-exec picks up some shares
3rd Feb 2016 15:15
(ShareCast News) - Engineering support services company Babcock International said non-executive director Jeff Randall purchased 1,134 shares at 8.81p each. This brings his total holding to 4,268 shares. On Tuesday, Babcock said its joint venture with Lockheed Martin, Ascent Flight Training, had
Read moreReNeuron raises £68.4m with Woodford support as annual losses widen
10th Jul 2015 09:05
Stem cell therapy company Reneuron Group has raised £68.4m to focus on its core product and nanomedicine cancer programme through to the first half of 2019, while final results highlighted progress of its other projects. A placing of £68.4m at a price of 5p per share saw star UK fund manager Neil Wo
Read moreReneuron on track for clinical milestones as studies get underway
2nd Sep 2014 08:51
Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials. The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have bot
Read moreSector movers: Weak results, outlook from Glaxo sink pharma stocks
23rd Jul 2014 14:17
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read moreReNeuron well set after 'transformational' year
18th Jun 2014 13:29
Stem cell treatment developer ReNeuron lost an increased £7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year. The AIM-listed compa
Read moreReNeuron seeks to expand board with new CEO
23rd Apr 2014 12:02
A new chief executive is being sought by AIM-listed stem cell specialist ReNeuron as it enters the next stage of its development. Current Chief Executive Michael Hunt will remain in the role until a replacement is recruited, when he will become Chief Financial Officer. Chairman Bryan Morton said:
Read moreReNeuron leases building for relocation of business
15th Apr 2014 12:23
AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales. The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next ye
Read moreUS foundation funds ReNeuron stem cell therapy
11th Mar 2014 12:48
A US-based charity has agreed to provide funding and access to clinical expertise for ReNeuron's retinal stem cell therapy candidate for a degenerative eye disease. Shares in ReNeuron rose 8.8% to 3.54p on the news. The Foundation for Fighting Blindess has agreed to provide further funding toward
Read moreReNeuron announces capital increase, funds to enter capital structure
22nd Jul 2013 10:50
Lifesciences group ReNeuron has announced that it has successfully raised 33m pounds in fresh funding to finance its research into stem-cell development, although it had to offer a small discount for the new equity. Significantly, three new investment funds are to enter its shareholder register with
Read moreReNeuron jumps on stem cell study results
28th May 2013 10:39
Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The group said that the primary aim of the study was to test the safety and toler
Read moreReNeuron Group to begin stem cell treatment of critical limb ischaemia
26th Mar 2013 09:45
ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia. Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to am
Read moreReNeuron Group wins grants for stem cell therapy development
11th Mar 2013 08:31
ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy. The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. The first award of £0.4m will be used for
Read moreReNeuron Group edges further in stem cell therapy research for stroke patients
29th Jan 2013 10:29
ReNeuron Group received the green light to complete the final stages of first phase safety testing of its ReN001 stem cell therapy for disabled stroke patients in Scotland, the company announced Tuesday. The ReN001 stem cell therapy was being administered in ascending doses to a total of 12 stroke
Read moreAngel Biotech signs new contract with ReNeuron
5th Nov 2012 08:33
Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year. The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001
Read more